Karo Pharma AB | Balance Sheet

Fiscal year is January-December. All values SEK Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
23
52
76
121
839
399
Total Accounts Receivable
9
2
37
85
171
309
Inventories
-
-
43
79
110
192
Other Current Assets
4
3
6
6
32
12
Total Current Assets
36
57
163
291
1,151
912
Net Property, Plant & Equipment
5
4
6
12
14
17
Total Investments and Advances
-
-
-
-
28
-
Intangible Assets
-
-
476
1,432
2,923
5,425
Other Assets
-
-
-
-
-
-
Total Assets
40
61
649
1,853
4,336
7,002
ST Debt & Current Portion LT Debt
-
2
92
376
816
Accounts Payable
4
4
29
37
59
Income Tax Payable
-
-
3
10
22
Other Current Liabilities
13
14
101
34
138
Total Current Liabilities
16
20
225
457
1,035
Long-Term Debt
-
-
21
540
1,448
Deferred Taxes
-
-
33
50
15
Other Liabilities
-
-
-
-
4
Total Liabilities
16
20
284
1,136
2,750
Common Equity (Total)
24
41
363
717
1,586
Total Shareholders' Equity
24
41
363
717
1,586
Total Equity
24
41
365
717
1,587
Liabilities & Shareholders' Equity
40
61
649
1,853
4,336
Accumulated Minority Interest
-
-
-
-
1

About Karo Pharma AB

View Profile
Address
Nybrokajen 7
Stockholm AB 111 48
Sweden
Employees -
Website http://www.karopharma.se
Updated 07/08/2019
Karo Pharma AB is a healthcare company, which engages in the research, development, and distribution of innovative drugs for key medical needs. It focuses on the project portfolio consists of RORgamma, Multiple Sclerosis and Cancer, and T268A Common Cold Spray. The company was founded in 1987 and is headquartered in Stockholm, Sweden.